KENSUKE MORIWAKI

モリワキケンスケ | KENSUKE MORIWAKI

Affiliation and department：
Job title： Assistant Professor

Research field (3)： Healthcare management, medical sociology , Hygiene and public health (non-laboratory) , Clinical pharmacy

Research keywords (8)：薬剤経済学 , 費用対効果評価 , 医療経済評価 , 医療技術評価 , 生物統計学 , 医療統計学 , 医療経済学 , 費用効果分析

Research theme for competitive and other funds (18)：

2020 - 2025 二次性MRに対するカテーテル修復術のレスポンダー同定と費用対効果分析
2020 - 2024 Development of the new healthcare decision support system integrating multiple value-based criteria including cost-effectiveness
2018 - 2022 脳卒中のLearning Healthcare Systemに関する研究
2017 - 2022 粒子線治療の費用対効果評価のための標準的な手法とデータに関する研究
2017 - 2020 経カテーテル大動脈弁置換術の有効性・最適化・費用対効果を明らかにする研究

Show all

Papers (40)：

Tomomi Maeda, Kensuke Moriwaki, Kosuke Morimoto, Xiuting Mo, Takashi Yoshioka, Rei Goto, Kojiro Shimozuma. Cost-effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan. Value in health regional issues. 2024. 40. 118-126
Kosuke Morimoto, Kensuke Moriwaki, Kojiro Shimozuma, Takeo Nakayama. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan. Journal of gastroenterology. 2023
Eri Hoshino, Kensuke Moriwaki, Kosuke Morimoto, Kotomi Sakai, Nobuyuki Shimohata, Keiko Konomura, Kevin Y. Urayama, Mitsuyoshi Suzuki, Kojiro Shimozuma. Cost-effectiveness analysis of universal screening for biliary atresia in Japan. The Journal of Pediatrics. 2022
Xiuting Mo, Kensuke Moriwaki, Kosuke Morimoto, Kojiro Shimozuma. Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan. Clinical drug investigation. 2022. 42. 7. 599-609
Andreas Haryono, Koji Ikeda, Dhite Bayu Nugroho, Takehiro Ogata, Yumika Tsuji, Satoaki Matoba, Kensuke Moriwaki, Hiroshi Kitagawa, Michihiro Igarashi, Ken-Ichi Hirata, et al. ChGn-2 Plays a Cardioprotective Role in Heart Failure Caused by Acute Pressure Overload. Journal of the American Heart Association. 2022. 11. 7. e023401

ｍore...

MISC (111)：

森脇健介. 日本におけるBenefit and Budget Impact Calculatorの活用可能性. 日本骨粗鬆症学会雑誌. 2021. 7. Suppl.1. 212-212
森本航輔, 森脇健介, 兼安貴子, 中山仁美, 下妻晃二郎. 切除不能膵癌に対するゲムシタビン+ナブパクリタキセル併用療法の費用対効果分析. 日本医療・病院管理学会誌. 2020. 57. Suppl. 186-186
森脇健介. 【骨粗鬆症最新の知見に基づいた治療薬の考え方・使い方】骨粗鬆症治療における医療経済評価. 薬局. 2020. 71. 11. 3360-3365
森脇健介. 【コモンディジーズとしての骨粗鬆症診療】総論骨粗鬆症の基礎知識骨粗鬆症と医療経済. 診断と治療. 2020. 108. 9. 1147-1151
森脇健介. 【医療経済とプレシジョンメディシン】医療経済評価の基本手法と分析事例. Precision Medicine. 2020. 3. 10. 884-887

ｍore...

Books (10)：

ｍore...

Lectures and oral presentations (22)：

日本における費用対効果評価の考え方
(医療経済・QOL 研究センター第6回セミナー 2019)
医療技術の費用対効果評価の基本
(第26回新潟リウマチ医の会 2019)
医療統計学の基礎と臨床試験の読み方
(平成30年度第2回兵庫県立病院薬剤師研修 2018)
医薬品の費用対効果の評価と活用-くすりの価値をどう測る?-
(第68回日本薬学会近畿支部総会・大会招待講演 2018)
医療技術の費用対効果評価-基本手法と事例-
(第91回日本整形外科学会学術総会教育研修講演 2018)

ｍore...

Education (5)：

2010 - 2013 Niigata University of Health and Welfare Graduate School of Health and Welfare
2007 - 2008 Kobe University Graduate School of Medicine
2005 - 2007 Kobe University Graduate School of Medicine Faculty of Biomedical Sciences
2002 - 2005 Hiroshima University School of Integrated Arts and Sciences Integrated Arts and Sciences
2001 - 2002 Hiroshima University School of Letters Humane Studies

Professional career (3)：

Work history (10)：

2022/04 - 現在 Ritsumeikan University
2019/10 - 現在 Ritsumeikan University Research Organization of Science and Technology
2018/07 - 2022/03 国立循環器病研究センター客員研究員(兼任)
2017/03 - 2020/03 国立保健医療科学院客員研究員(兼任)
2018/04 - 2019/09 Kobe Pharmaceutical University Faculty of Pharmacy

Show all

Awards (2)：

2013 - 日本骨粗鬆症学会第8回森井賞
2007 - International Society for Pharmacoeconomics and Outcomes Research ISPOR Best Contributed Poster Presentation Awards

Association Membership(s) (5)：

THE BIOMETRIC SOCIETY OF JAPAN , 日本臨床試験学会 , 日本骨粗鬆症学会 , ISPOR日本部会 , International Society for Pharmacoeconomics and Outcomes Research

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page